Conmed Corporation delivered better-than-expected quarterly results on July 30, with adjusted earnings per share climbing 17.3% to $1.15, exceeding analyst estimates of $1.12. Revenue also slightly surpassed expectations at $342.3 million versus the projected $338.4 million. Despite these positive figures, investors remained unimpressed as the stock dipped 0.3% in after-hours trading to $50.29, significantly below its 52-week high of $78.19. Behind the headline numbers, the medical device company’s modest 3.1% revenue growth raised concerns, particularly in its orthopedics division, which grew just 0.8% amid persistent supply chain difficulties. The general surgery segment performed better with 4.4% growth, driven by the AirSeal platform for minimally invasive procedures and Buffalo Filter smoke evacuation systems.
Recovery Efforts Underway
Management acknowledged market share losses while outlining plans to address ongoing challenges. Conmed has engaged a top consulting firm to optimize its supply chain, targeting annual savings of $20 million to improve operational efficiency. The company aims to resolve these issues by the end of 2025, though investors appear skeptical given the prolonged nature of these difficulties. For fiscal 2025, Conmed maintained its revenue forecast between $1.356 billion and $1.378 billion, with adjusted earnings per share projected at $4.40 to $4.55. The company’s debt ratio has improved to 3.1, indicating financial stability, but operational challenges and sluggish growth continue to dampen investor enthusiasm.
Ad
Conmed Stock: Buy or Sell?! New Conmed Analysis from February 7 delivers the answer:
The latest Conmed figures speak for themselves: Urgent action needed for Conmed investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Conmed: Buy or sell? Read more here...
